Results 11 to 20 of about 6,976 (185)

Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis

Frontiers in Oncology, 2023
IntroductionMany systemic treatment options are available for patients with human epidermal growth factor 2 (HER2)-positive breast cancer brain metastases.
Xingfa Huo, Xingfa Huo, Guoshuang Shen, Tianzhuo Wang, Jinming Li, Qiqi Xie, Zhen Liu, Miaozhou Wang, Fuxing Zhao, Dengfeng Ren, Jiuda Zhao   +10 more
doaj   +1 more source

Fam-trastuzumab deruxtecan-nxki (Enhertu®): A narrative drug review

Cancer Research, Statistics, and Treatment, 2022
Human epidermal growth factor receptor 2 (HER2) is a subset of the epidermal growth factor receptor family that expresses tyrosine kinase activity. Dimerization of the receptor initiates various cellular signaling pathways, ultimately leading to the ...
Ryan Varghese, Niraja Soman, Jainam Karsiya, Nimesh Bafna, Shona Nag   +4 more
doaj   +1 more source

Dose-reduced trastuzumab deruxtecan can be safely used in liver failure and active leptomeningeal metastases

Current Problems in Cancer: Case Reports, 2020
Trastuzumab deruxtecan has been shown to have responses in heavily pretreated patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer.
Nicole Higashiyama, Julie Nangia, Maryam Nemati Shafaee, Nan Chen, Binu Liz Michael, Mothaffar Rimawi, Valentina Hoyos   +6 more
doaj   +1 more source

Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines

Therapeutic Advances in Medical Oncology, 2022
Background: Evidence to date supports continued human epidermal growth factor receptor 2 (HER2) suppression beyond progression on HER2-directed therapy for advanced HER2-positive breast cancer.
Christine Simmons, Daniel Rayson, Anil Abraham Joy, Jan-Willem Henning, Julie Lemieux, Heather McArthur, Paul B. Card, Rebecca Dent, Christine Brezden-Masley   +8 more
doaj   +1 more source

[Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model.

PLoS ONE, 2019
[Fam-] trastuzumab deruxtecan (DS-8201a) is a HER2 (ERBB2)-targeting antibody-drug conjugate, composed of a HER2-targeting antibody and a topoisomerase I inhibitor, exatecan derivative, that has antitumor effects in preclinical xenograft models and ...
Tomomi Nakayama Iwata, Kiyoshi Sugihara, Teiji Wada, Toshinori Agatsuma   +3 more
doaj   +1 more source

Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers

Cancer Control, 2022
Epidermal growth factor receptor 2 (EGFR2, also known as HER2) overexpression and/or amplification confers a more aggressive clinical behavior but also represents a therapeutic opportunity for targeted therapies in breast cancer (BC).
Alessandro Rizzo MD, Antonio Cusmai MD, Raffaella Massafra PhD, Samantha Bove PhD, Maria Colomba Comes PhD, Annarita Fanizzi PhD, Gennaro Gadaleta-Caldarola MD, Donato Oreste MD, Alfredo Zito MD, Francesco Giotta MD, Vito Lorusso MD, Gennaro Palmiotti MD   +11 more
doaj   +1 more source

Targeted and Immunotherapy Approaches in HER2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma: A New Era [PDF]

Journal of Immunotherapy and Precision Oncology, 2023
HER2-targeted therapy with the HER2 monoclonal antibody trastuzumab has achieved impressive outcomes in the first-line settings of patients with advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma overexpressing HER2. However, considering
Maluki Radford, Hassan Abushukair, Stijn Hentzen, Ludimila Cavalcante, Anwaar Saeed   +4 more
doaj   +1 more source

Sequencing Antibody Drug Conjugates in Breast Cancer: Exploring Future Roles

Current Oncology, 2023
Antibody drug conjugates (ADCs) have emerged as a highly effective treatment strategy across breast cancer (BC) subtypes, including human epidermal growth factor receptor 2-positive (HER2+), hormone-receptor positive (ER/PR+), and triple-negative breast ...
Mary Anne Fenton, Paolo Tarantino, Stephanie L. Graff   +2 more
doaj   +1 more source

Trastuzumab deruxtecan (DS-8201) plus bevacizumab for HER2-low metastatic breast cancer with malignant pleural effusion: a case report and literature review. [PDF]

Front Oncol
Han H, Liu J, Wang C, Yang M, Liu J, Sun P.   +5 more
europepmc   +2 more sources

The Rapidly Changing Treatment Landscape of Systemic Therapy for HER-2 Positive Metastatic Breast Cancer

healthbook TIMES. Oncology Hematology, 2021
Human epidermal growth factor receptor 2 (HER-2) overexpressed breast cancer has traditionally been considered as an aggressive disease with high risk of systemic and brain metastases and poor prognosis.
Larissa Russo-Vorms, Christoforos Astaras, José Sandoval, Maxime Borgeaud, Alexandre Bodmer   +4 more
doaj   +1 more source